Who owns Benegrip?
Benegrip is owned by Hypera (Brazil, B3: HYPE3).[1]
This ownership is reported in official statements but has not yet been matched to a regulatory filing.
Key facts
- Current owner
- Hypera Pharma reported
- Owned since
- Not recorded
- Previous owner
- None recorded
- Owner HQ
- 🇧🇷 Brazil, São Paulo
- Origin
- 🇧🇷 Brazil
- Category
- Consumer health › Over-the-counter medicine › Cold
- Parent ticker
- B3: HYPE3
- Last verified
- · 1 sources
About Benegrip
Benegrip is Hypera Pharma's flu and cold remedy, combining dipyrone as a painkiller, chlorphenamine maleate as an antihistamine and caffeine. The line includes Benegrip Multi day and night versions, a children's range with Benedesc Plus syrup and Benegrip Imuno Kids chewable vitamins, and Benetosse cough syrup. Footballer Estêvão signed as brand ambassador until 2029.
Ownership timeline of Benegrip
Where Benegrip sits in Hypera
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Open the full Hypera ownership tree →
Other brands owned by Hypera in consumer health
Latest news about Benegrip
No tagged news items yet. Deals, regulatory actions and recalls are added from SEC filings, regulators and trade press; only titles and links are stored.
Headlines link to the original publisher. Brandtree does not reproduce article text.
Frequently asked questions
Who is the parent company of Benegrip?
The parent company of Benegrip is Hypera, a publicly listed company headquartered in Brazil.
Is Benegrip Brazilian?
Yes. Benegrip originated in Brazil and its owner, Hypera, is also headquartered in Brazil.
Is Benegrip still owned by Hypera?
Yes. As of 16 September 2026, Benegrip is still owned by Hypera. The ownership record was last checked against primary sources on that date.
Sources (1) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Hypera Pharma — Corporate Profile (investor relations, updated 18 June 2026) — Hypera Pharma, Official document, published 18 June 2026; retrieved 16 September 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.